Search results
Results From The WOW.Com Content Network
AstraZeneca is a global company that transforms healthcare with science. The web page does not show the logo of AstraZeneca, but it has information about its products, pipeline, sustainability and stories.
Find the latest information on AstraZeneca's financial performance, clinical trials, sustainability and governance. Contact the investor relations team, access annual reports and view upcoming events.
AstraZeneca is a science-led, patient-focused pharmaceutical company that transforms healthcare by unlocking the power of science. Learn about its strategy, organisation, values, sustainability, and careers.
We’ve put Digital at the heart of AstraZeneca and how it shapes the future of Pharma. Backed by investment at every step, we harness the latest technology, data and cutting-edge ways of working to achieve new, better outcomes.
AstraZeneca is a global, patient-focused pharmaceutical company that seeks to realise the potential of what science can do. The annual report covers its strategic overview, disease area review, sustainability highlights and financial performance in 2021.
AstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas.
Find the contact details for AstraZeneca offices worldwide, including the UK and US. For medical enquiries, product information, or supply chain issues, call the relevant numbers or visit the websites.
Learn how AstraZeneca is a global, science-led, patient-focused pharmaceutical business, with a growing portfolio of medicines and a pipeline of new modalities. See the financial and operational performance, the achievements in 2023, and the commitments to people, society and the planet.
Meet the Board of Directors and the Senior Executive Team of AstraZeneca, a global biopharmaceutical company. Pascal Soriot is the CEO and Executive Director since 2012.
AstraZeneca reports strong growth and upgrades FY 2024 guidance for Total Revenue and Core EPS. The company also highlights its pipeline potential with disruptive technologies and positive Phase III studies.